查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108290

基於CRISPR的基因治療市場的分析和至2035年的預測：按類型、產品、服務、技術、應用、流程、最終用戶、解決方案和階段

CRISPR Based Gene Therapies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Solutions, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球基於CRISPR的基因治療市場預計將從2025年的32億美元成長到2035年的90億美元，CAGR為10.8%。該成長主要得益於基因編輯技術的進步、基因研究經費的增加以及對創新療法需求日益成長的遺傳疾病。基於CRISPR的基因療法市場競爭格局相對集中，其中癌症治療主導地位，其次是罕見遺傳疾病和感染疾病的治療。 CRISPR技術的持續進步以及體內和體外基因編輯應用範圍的不斷擴大，都為市場發展提供了支持。臨床研究的增加、監管政策的改善以及對基因治療投資的不斷成長，都在加速市場發展。成熟的製藥公司、生技公司和新興創新企業共同構成了該市場的競爭格局，它們都致力於提高基因編輯過程的精準性和安全性。與學術機構的策略合作、研究合作與授權交易推動創新，加強產品平臺，並支持下一代基於 CRISPR 的療法的商業化。

依技術分類，基因編輯市場可分為 CRISPR/Cas9、CRISPR/Cpf1、CRISPR/Cas12a、CRISPR/Cas13 及其他技術。其中，CRISPR/Cas9 因其編輯效率高、設計簡便以及在研究和治療應用中擁有廣泛的檢驗記錄，在基於 CRISPR 的基因治療市場中佔據最大佔有率。憑藉強大的臨床項目儲備，CRISPR/Cas9 已廣泛應用於遺傳疾病、癌症和罕見疾病的治療研發。同時，CRISPR/Cas12a 和 CRISPR/Cas13 因其獨特的靶點選擇能力、更高的特異性以及在基因編輯和 RNA 標靶治療領域不斷擴展的應用範圍而備受關注，預計將推動未來市場成長。

市場區隔
類型 體內、體內、其他
產品 CRISPR酶、CRISPR庫、CRISPR試劑盒、其他
服務 基因編輯服務、客製化 CRISPR 服務、諮詢服務、其他
技術 CRISPR/Cas9、CRISPR/Cpf1、CRISPR/Cas12a、CRISPR/Cas13 、其他
應用領域 癌症治療、罕見疾病、遺傳性疾病、心血管疾病、感染疾病、其他
過程 基因敲除、基因敲入、基因活化、基因抑制、其他
最終用戶 生技公司、製藥公司、學術和研究機構、受託研究機構、其他
解決方案 治療方案、研究方案、診斷方案、其他
階段 藥物發現、臨床前研究、臨床試驗、商業化等領域。

從應用領域分類，市場可分為癌症治療、罕見疾病、遺傳性疾病、心血管疾病、感染疾病和其他領域。其中，遺傳性疾病領域佔據最大佔有率，這主要得益於人們對開發針對鐮狀細胞貧血症、BETA-地中海貧血和Duchenne氏肌肉失養症遺傳性疾病的一次性治癒方法的日益關注。不斷取得的臨床成功、監管部門的支持以及對基因編輯研究投入的增加，持續推動這一領域的成長。癌症治療領域也正經歷快速成長，因為CRISPR技術擴大用於改造免疫細胞、改進細胞療法，並為血液腫瘤和固體癌的精準治療提供可能。

區域概覽

北美憑藉其成熟的生物技術產業、強大的臨床研究生態系統以及對基因編輯技術的巨額投資，佔據了基於CRISPR的基因治療市場最大佔有率。領先的生物技術公司、學術研究機構和製藥公司的存在，加速開發用於治療罕見遺傳疾病、癌症和其他遺傳疾病的基於CRISPR的療法。強而有力的政府資助、有利於臨床研究的法規結構以及產業界與研究機構之間的積極合作，進一步推動了市場擴張。持續的創新、不斷增加的臨床試驗活動以及高額的醫療保健支出，鞏固了北美在全球市場的主導地位。

亞太地區預計將成為CRISPR基因治療領域成長最快的市場，這主要得益於生物技術研究投入的增加、基因組醫學計畫的拓展以及醫療基礎設施的改善。中國、日本、韓國和新加坡正積極透過政府主導的措施和官民合作關係來推進基因編輯研究。遺傳疾病盛行率的上升、臨床試驗活動的活性化以及對精準醫療需求的成長加速市場成長。隨著生物技術新創企業生態系統的不斷壯大、研究經費的增加以及國際合作的加強，亞太地區正逐步成為CRISPR基因治療領域成長最快的區域市場。

主要趨勢和促進因素

新一代 CRISPR 平台的擴展推動基因療法的發展：

包括鹼基編輯、先導編輯和多重基因編輯在內的先進CRISPR技術的發展，是基於CRISPR的基因治療市場的一大趨勢。這些新世代平台能夠實現極為精準的基因修飾，同時提高安全性並減少脫靶效應。研究人員正不斷探索新型遞送系統，例如體內基因編輯和脂質奈米顆粒，以拓展治療應用。針對罕見疾病、癌症、血液疾病和遺傳性疾病的臨床試驗數量不斷增加，進一步加速了創新，並增強了基於CRISPR療法的臨床潛力。

遺傳疾病負擔日益加重，推動市場成長：

遺傳性疾病和罕見疾病的日益普遍是推動基於 CRISPR 的基因治療市場發展的主要動力。由於傳統療法通常只能緩解症狀，因此人們對能夠糾正致病基因突變的療法有著強烈的需求。生物技術研發投入的增加、支持先進療法的法規結構、臨床試驗活動的活性化以及學術機構與製藥公司之間合作的拓展，都在加速產品開發和商業化進程，顯著促進了全球市場的成長。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 體內
    • 體外
    • 其他
  • 市場規模及預測：依產品分類
    • CRISPR酶
    • CRISPR庫
    • CRISPR試劑盒
    • 其他
  • 市場規模及預測：依服務分類
    • 基因編輯服務
    • 客製化CRISPR服務
    • 諮詢服務
    • 其他
  • 市場規模及預測：依技術分類
    • CRISPR/Cas9
    • CRISPR/Cpf1
    • CRISPR/Cas12a
    • CRISPR/Cas13
    • 其他
  • 市場規模及預測：依應用領域分類
    • 癌症治療
    • 罕見疾病
    • 遺傳性疾病
    • 心血管疾病
    • 感染疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 學術研究機構
    • 受託研究機構
    • 其他
  • 市場規模及預測：依製程分類
    • 基因敲除
    • 基因敲入
    • 基因啟用設定
    • 基因抑制
    • 其他
  • 市場規模及預測：依解決方案分類
    • 治療方案
    • 研究解決方案
    • 診斷解決方案
    • 其他
  • 市場規模及預測：依階段分類
    • 發現
    • 臨床前階段
    • 臨床試驗
    • 商業化
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Editas Medicine
  • CRISPR Therapeutics
  • Intellia Therapeutics
  • Beam Therapeutics
  • Caribou Biosciences
  • Sangamo Therapeutics
  • Precision BioSciences
  • Graphite Bio
  • Verve Therapeutics
  • Mammoth Biosciences
  • Cellectis
  • Horizon Discovery
  • Poseida Therapeutics
  • Arbor Biotechnologies
  • eGenesis
  • Inscripta
  • Synthego
  • Pairwise Plants
  • Tessera Therapeutics
  • Locus Biosciences

第9章 關於我們

簡介目錄
Product Code: GIS10919

The global CRISPR Based Gene Therapies Market is projected to grow from $3.2 billion in 2025 to $9.0 billion by 2035, at a compound annual growth rate (CAGR) of 10.8%. Growth is driven by advancements in gene editing technology, increased funding for genetic research, and rising prevalence of genetic disorders necessitating innovative therapeutic solutions. The CRISPR Based Gene Therapies Market exhibits a moderately consolidated competitive landscape, led by oncology therapies, followed by treatments for rare genetic disorders and infectious diseases. The market is driven by expanding applications in both in vivo and ex vivo gene editing, supported by continuous advancements in CRISPR technology. Increasing clinical research, regulatory progress, and growing investment in gene therapy are accelerating market development. Competition is shaped by established pharmaceutical companies, biotechnology firms, and emerging innovators focused on improving editing precision and safety. Strategic partnerships, research collaborations, and licensing agreements with academic institutions are fostering innovation, strengthening product pipelines, and supporting the commercialization of next-generation CRISPR-based therapies.

Based on Technology, the market is segmented into CRISPR/Cas9, CRISPR/Cpf1, CRISPR/Cas12a, CRISPR/Cas13, and Others. Among these, CRISPR/Cas9 accounts for the largest share of the CRISPR-based gene therapies market due to its high editing efficiency, ease of design, and extensive validation across research and therapeutic applications. It is widely used for developing treatments for genetic disorders, cancer, and rare diseases, supported by a strong pipeline of clinical programs. Meanwhile, CRISPR/Cas12a and CRISPR/Cas13 are gaining traction because of their unique targeting capabilities, improved specificity, and expanding applications in gene editing and RNA-targeted therapeutics, contributing to future market growth.

Market Segmentation
TypeIn Vivo, Ex Vivo, Others
ProductCRISPR Enzymes, CRISPR Libraries, CRISPR Kits, Others
ServicesGene Editing Services, Custom CRISPR Services, Consultation Services, Others
TechnologyCRISPR/Cas9, CRISPR/Cpf1, CRISPR/Cas12a, CRISPR/Cas13, Others
ApplicationCancer Therapy, Rare Diseases, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, Others
ProcessGene Knockout, Gene Knock-In, Gene Activation, Gene Repression, Others
End UserBiotechnology Companies, Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, Others
SolutionsTherapeutic Solutions, Research Solutions, Diagnostic Solutions, Others
StageDiscovery, Preclinical, Clinical Trials, Commercialization, Others

Based on Application, the market is segmented into Cancer Therapy, Rare Diseases, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, and Others. Among these, Genetic Disorders represent the largest segment owing to the growing focus on developing one-time curative therapies for inherited diseases such as sickle cell disease, beta-thalassemia, and Duchenne muscular dystrophy. Increasing clinical success, regulatory support, and investment in gene-editing research continue to drive this segment. Cancer Therapy is also witnessing rapid growth as CRISPR technologies are increasingly utilized for engineering immune cells, improving cell-based therapies, and enabling precision oncology approaches for both hematological and solid tumors.

Geographical Overview

North America holds the largest share of the CRISPR-based gene therapies market due to its well-established biotechnology sector, robust clinical research ecosystem, and significant investments in gene-editing technologies. The presence of leading biotechnology companies, academic research centers, and pharmaceutical firms has accelerated the development of CRISPR-based therapies for rare genetic disorders, cancer, and inherited diseases. Strong government funding, favorable regulatory frameworks for clinical research, and active collaborations between industry and research institutions further support market expansion. Continuous innovation, increasing clinical trial activity, and high healthcare expenditure reinforce North America's leadership in the global market.

Asia-Pacific is projected to be the fastest-growing market for CRISPR-based gene therapies, driven by increasing investments in biotechnology research, expanding genomic medicine programs, and improving healthcare infrastructure. China, Japan, South Korea, and Singapore are actively promoting gene-editing research through government initiatives and public-private partnerships. Rising prevalence of genetic diseases, growing clinical trial activities, and increasing demand for precision medicine are accelerating market growth. Expanding biotechnology startups, favorable research funding, and international collaborations are strengthening innovation capabilities, positioning Asia-Pacific as the fastest-growing regional market for CRISPR-based gene therapies.

Key Trends and Drivers

Expansion of Next-Generation CRISPR Platforms Is Advancing Gene Therapy Development:

The development of advanced CRISPR technologies, including base editing, prime editing, and multiplex gene editing, is a major trend in the CRISPR based gene therapies market. These next-generation platforms enable highly precise genetic modifications with improved safety and reduced off-target effects. Researchers are increasingly exploring in vivo gene editing and novel delivery systems such as lipid nanoparticles to expand therapeutic applications. The growing number of clinical trials targeting rare diseases, cancer, blood disorders, and inherited conditions is further accelerating innovation and strengthening the clinical potential of CRISPR-based therapies.

Rising Burden of Genetic Diseases Is Driving the Market Growth:

The increasing prevalence of inherited genetic disorders and rare diseases is a key driver of the CRISPR based gene therapies market. Conventional treatment approaches often provide only symptomatic relief, creating strong demand for therapies capable of correcting disease-causing genetic mutations. Growing investments in biotechnology research, supportive regulatory pathways for advanced therapies, increasing clinical trial activity, and expanding collaborations between academic institutions and pharmaceutical companies are accelerating product development and commercialization, contributing significantly to global market growth.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Solutions
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 In Vivo
    • 4.1.2 Ex Vivo
    • 4.1.3 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 CRISPR Enzymes
    • 4.2.2 CRISPR Libraries
    • 4.2.3 CRISPR Kits
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Editing Services
    • 4.3.2 Custom CRISPR Services
    • 4.3.3 Consultation Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR/Cas9
    • 4.4.2 CRISPR/Cpf1
    • 4.4.3 CRISPR/Cas12a
    • 4.4.4 CRISPR/Cas13
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Cancer Therapy
    • 4.5.2 Rare Diseases
    • 4.5.3 Genetic Disorders
    • 4.5.4 Cardiovascular Diseases
    • 4.5.5 Infectious Diseases
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Academic & Research Institutes
    • 4.6.4 Contract Research Organizations
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Gene Knockout
    • 4.7.2 Gene Knock-In
    • 4.7.3 Gene Activation
    • 4.7.4 Gene Repression
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Solutions (2020-2035)
    • 4.8.1 Therapeutic Solutions
    • 4.8.2 Research Solutions
    • 4.8.3 Diagnostic Solutions
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical
    • 4.9.3 Clinical Trials
    • 4.9.4 Commercialization
    • 4.9.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Solutions
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Solutions
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Solutions
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Solutions
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Solutions
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Solutions
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Solutions
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Solutions
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Solutions
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Solutions
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Solutions
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Solutions
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Solutions
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Solutions
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Solutions
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Solutions
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Solutions
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Solutions
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Solutions
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Solutions
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Solutions
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Solutions
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Solutions
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Solutions
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Editas Medicine
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 CRISPR Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Intellia Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Beam Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Caribou Biosciences
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sangamo Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Precision BioSciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Graphite Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Verve Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Mammoth Biosciences
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Cellectis
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Horizon Discovery
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Poseida Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Arbor Biotechnologies
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 eGenesis
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Inscripta
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Synthego
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Pairwise Plants
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Tessera Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Locus Biosciences
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us